| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/10/2004 | WO2004041211A3 INHIBITORS OF β-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER’S DISEASE OR MILD COGNITIVE IMPAIRMENT |
| 09/10/2004 | WO2004039829A3 Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
| 09/10/2004 | WO2004039426A3 Transdermal delivery system for water insoluble drugs |
| 09/10/2004 | WO2004039409A3 Composition comprising activators of ik potassium channels and calcineurin antagonists and use thereof |
| 09/10/2004 | WO2004037783A3 Treatment of cognitive impairment using a selective dopamine d1 receptor agonist |
| 09/10/2004 | WO2004037226B1 Pharmaceutical compositions containing venlafaxine |
| 09/10/2004 | WO2004034985A3 Chemical compounds |
| 09/10/2004 | WO2004031210A3 Optimized multi-epitope constructs and uses thereof |
| 09/10/2004 | WO2004028451A3 β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA |
| 09/10/2004 | WO2004022523A3 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| 09/10/2004 | WO2004022128A3 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
| 09/10/2004 | WO2004017920B1 Novel biphenyl and biphenyl-like cannabinoids |
| 09/10/2004 | WO2004016260A8 Therapeutic use of fused bicyclic or tricyclic amino acids |
| 09/10/2004 | WO2004014352A3 Methods for treating carbonic anhydrase mediated disorders |
| 09/10/2004 | WO2004009030A3 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| 09/10/2004 | WO2004007444A3 N-hydroxyamide derivatives possessing antibacterial activity |
| 09/10/2004 | WO2004000215A3 Hydroxamate derivatives of non-steroidal anti-inflammatory drugs |
| 09/10/2004 | WO2003106970A3 P27 prevents cellular migration |
| 09/10/2004 | WO2003101281A3 Method for reducing obstructive hydrocephalus |
| 09/10/2004 | WO2003090671A3 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| 09/10/2004 | WO2003079984A3 Substituted tetracycline compounds |
| 09/10/2004 | WO2003070191A3 Tamper-resistant transdermal opioid delivery devices |
| 09/10/2004 | WO2003061652A8 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 09/10/2004 | WO2003053169A8 Soft drink replacer |
| 09/10/2004 | WO2003038129A3 Methods for assessing and treating leukemia |
| 09/10/2004 | WO2003030822A3 Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same |
| 09/10/2004 | WO2003030816A3 Combinatorial anti-acne compositions |
| 09/10/2004 | WO2002098890A3 MARKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 09/10/2004 | WO2002097053A3 Small molecule antagonists of bcl2 family proteins |
| 09/10/2004 | WO2002092840A3 Agents that regulate apoptosis |
| 09/10/2004 | WO2002064085A3 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 09/10/2004 | CA2556629A1 Opioid delivery system |
| 09/10/2004 | CA2555746A1 Use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea for the treatment of pancreatic cancer, soft-tissue sarcoma, testicular tumors, lymphoma, thymoma, wilm's tumors, renal carcinoma, melanoma, lung cancer, intracerebral metastasis, tumors in the head and neck region, and mammary carcinoma |
| 09/10/2004 | CA2517834A1 Method for selecting a candidate drug compound |
| 09/10/2004 | CA2517714A1 Polymorphs of s-omeprazole |
| 09/10/2004 | CA2517575A1 Growth promotion method |
| 09/10/2004 | CA2517416A1 Therapeutic compositions |
| 09/10/2004 | CA2517386A1 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis |
| 09/10/2004 | CA2517381A1 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis |
| 09/10/2004 | CA2517346A1 Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor |
| 09/10/2004 | CA2517321A1 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients |
| 09/10/2004 | CA2517308A1 Tailored treatment suitable for different forms of mastocytosis |
| 09/10/2004 | CA2517307A1 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments |
| 09/10/2004 | CA2517290A1 Muscle-building agent and preventive or remedy for muscle weakening |
| 09/10/2004 | CA2517289A1 Stable pharmaceutical composition of rabeprazole and processes for their preparation |
| 09/10/2004 | CA2517259A1 Induction of methylation of cpg sequences by dsrnas in mammalian cells |
| 09/10/2004 | CA2517256A1 Aminoheteroaryl compounds as protein kinase inhibitors |
| 09/10/2004 | CA2517104A1 Anti-influenza virus compounds comprising biflavonoid-sialic acid conjugates |
| 09/10/2004 | CA2517074A1 Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| 09/10/2004 | CA2517052A1 Polyvalent immunogen |
| 09/10/2004 | CA2517007A1 Therapeutic malonic acid/acetic acid c60 tri-adducts of buckminsterfullerene and methods related thereto |
| 09/10/2004 | CA2516900A1 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
| 09/10/2004 | CA2516824A1 Pyrazolo[1,5-a]pyrimidine derivatives |
| 09/10/2004 | CA2516786A1 Treatment of excessive osteolyisis with indolinone compounds |
| 09/10/2004 | CA2516730A1 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases |
| 09/10/2004 | CA2516710A1 Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
| 09/10/2004 | CA2516705A1 Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
| 09/10/2004 | CA2516684A1 Selective non-steroidal glucocorticoid receptor modulators |
| 09/10/2004 | CA2516653A1 Serotonin and catecholamine system segment optimization technology |
| 09/10/2004 | CA2516651A1 Methods of screening for trpm5 modulators |
| 09/10/2004 | CA2516633A1 Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament |
| 09/10/2004 | CA2516626A1 Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments |
| 09/10/2004 | CA2516620A1 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis |
| 09/10/2004 | CA2516618A1 Pharmaceutical composition for treatment of drug dependence |
| 09/10/2004 | CA2516573A1 Diarylcycloalkyl derivatives, method for their production and their use as medicaments |
| 09/10/2004 | CA2516563A1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 09/10/2004 | CA2516522A1 Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors |
| 09/10/2004 | CA2516459A1 Pharmaceutical compositions for nasal delivery |
| 09/10/2004 | CA2516418A1 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| 09/10/2004 | CA2516399A1 Pharmaceutical compositions of safingol and methods of using the same |
| 09/10/2004 | CA2516239A1 Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| 09/10/2004 | CA2515842A1 Halogenated triptolide derivatives as immunomodulators and anticancer agents |
| 09/10/2004 | CA2515210A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 09/10/2004 | CA2514948A1 Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
| 09/10/2004 | CA2513443A1 Bioactive stents and methods for use thereof |
| 09/10/2004 | CA2512663A1 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
| 09/09/2004 | US20040177388 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 09/09/2004 | US20040176628 Purification of silicon oils with supercritical carbon dioxide extraction toproduce vitreoretinal silicone tamponade |
| 09/09/2004 | US20040176625 Kinesin motor modulators derived from the marine sponge Adocia |
| 09/09/2004 | US20040176610 Indolone oxazolidinones and derivatives thereof |
| 09/09/2004 | US20040176609 Compounds used as bactericides for treatment of infections |
| 09/09/2004 | US20040176606 Salt formation with benzooic acid in dilluent or carrier for heart disease and hypotensive agents |
| 09/09/2004 | US20040176605 Compounds as antumor agents or immunosuppressants |
| 09/09/2004 | US20040176601 Benzimisazo[4,5-f]isoquinolinone derivatives |
| 09/09/2004 | US20040176598 Azaindoles coupled with piperidine or piperazine and linker to cyclic group |
| 09/09/2004 | US20040176595 Glucocorticoid receptor modulators |
| 09/09/2004 | US20040176591 Novel synthesis and crystallization of peperazine ring-containing compounds |
| 09/09/2004 | US20040176587 Process for the preparation of l-ribavirin |
| 09/09/2004 | US20040176581 Method to produce a solid form of heparin |
| 09/09/2004 | US20040176570 Intermediates and enzymes of the non-mevalonate isoprenoid pathway |
| 09/09/2004 | US20040176476 Pharmaceutical composition |
| 09/09/2004 | US20040176475 Isolation of lutein from alfalfa |
| 09/09/2004 | US20040176470 suppressing, inhibiting, or reducing the incidence of pre-malignant lesions of prostate cancer |
| 09/09/2004 | US20040176469 Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| 09/09/2004 | US20040176468 Enantiomers of O-desmethyl venlafaxine |
| 09/09/2004 | US20040176467 treating a non-psychotic human subject to prevent the development of psychotic symptoms; administering a selective D3 antagonist in an amount and dosage regimen sufficient to suppress psychotic symptoms in at risk patient |
| 09/09/2004 | US20040176466 an effective amount of atomoxetine in combination with an inhibitor of Cytochrome P450s for patients who are extensive metabolizers; administering to a patient who has previously not responded to attention-deficit/hyperactivity disorder treatment |
| 09/09/2004 | US20040176465 Solid compositions containing fluoxetine and a coating |
| 09/09/2004 | US20040176464 pharmaceutical fluids for wet tissue, cosmetic lotions, mouthwash agents, lotions, bathing agents and deodorants; an inorganic salt, an organic acid salt, a nonionic surfactant and an ampholytic surfactant with an action to suppress precipiation |
| 09/09/2004 | US20040176463 Immediate release formulation of n-(2-propylpentanoyl)glycinamide |